Dr Adèle Thomas PhD

Research Fellow

Medical and Dental Sciences

Adèle Thomas

Contact details

Primary Care Clinical Sciences
School of Health and Population Sciences
College of Medical and Dental Sciences
University of Birmingham
B15 2TT


Adèle Thomas is a Research Fellow in the School of Health and Population Sciences.

Adèle has numerous publications in the areas of cannabinoid pharmacology and in rheumatology. She has presented her work at both national and international conferences.


  • PhD in Pharmacology, University of Aberdeen, 2005
  • BSc Biomed Sci (Hons) in Pharmacolgy, University of Aberdeen, 1999


Adèle Thomas qualified with a BSc Biomed Sci (Hons) in Pharmacology from the University of Aberdeen in 1999. After a short period of working in industry, she went on to complete a PhD in Pharmcology. Having gained her Phd in 2005, she then completed 2 post-doctoral research positions in the areas of cannabinoid receptor pharmacology and in rheumatology.

Currently, Adèle is a research fellow in the School of Health and Population Sciences and is co-ordinating a clinical trial that is investigating the impact of exercise on the vasomotor symptoms of menopausal women.


Current Research Activity:

  • Women’s health (menopause), physical activity, health services research, clinical trials,

Previous Research Activity:

  • Cannabinoid receptor pharmacology
  • Cannabinoid-based therapeutics
  • Rheumatic diseases
  • Bone metabolism regulation

Other activities

Member of British Pharmacological Society (2003 – current)


Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A. and Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British Journal of Pharmacology 150: 613-623

Pertwee, R., Thomas, A., Stevenson, L, Ross, R., Varvel, S., Lichtman, A., Martin, B., Razdan, R. (2007). The psychoactive plant cannabinoid, delta-9-tetrahydrocannabinol, is antagonized by delta-8- and delta-9-tetrahydrocannabivarin in mice in vivo, British Journal of Pharmacology 150, 586 - 594

Thomas, A., Stevenson, L. A., Wease, K. N., Price, M. R., Baillie, G., Ross, R. A., and Pertwee, R. G. (2005). “Evidence that the plant cannabinoid 9 tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.” British Journal of Pharmacology 146: 917-926

Price, M.R., Baillie, G., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., Walker, G., Westwood, P., Marrs, J., McLean, A., McIntosh, L., Goodwin, G., Thompson, F., Cowley, P., Christopoulos, A., Pertwee, R. G., and Ross, R. A. (2005). “Allosteric modulation of the cannabinoid CB1 receptor.” Molecular Pharmacology 68: 1484-1495

Thomas, A., Ross, R. A., Saha, B., Mahadevan, A., Razdan, R. K. and Pertwee, R. G. (2004). "6"-azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist." European Journal of Pharmacology 487(1-3): 213-221.

Pertwee, R. G. and Thomas A., (2008) “Therapeutic applications for agents that act at CB1 and CB2 receptors.” In Reggio P. H. (ed) The Cannabinoid Receptors. Human Press: Chapter 13

Thomas, A. and Pertwee, R. G. (2004) “The bioassay of cannabinoids using the mouse isolated vas deferens.” In Onaivi, E. M. (ed) Marijuana and Cannabinoid Research: Humana Press: Chapter 11

Back to top